Please login to the form below

Not currently logged in
Email:
Password:

ticagrelor

This page shows the latest ticagrelor news and features for those working in and with pharma, biotech and healthcare.

AZ expects return to growth this year after 2017 decline

AZ expects return to growth this year after 2017 decline

The contribution of these drugs as well as blockbuster sales for antiplatelet therapy Brilinta (ticagrelor) and diabetes drug Farxiga (dapagliflozin) allowed AZ to boost operating profit by 2% to $6.86bn

Latest news

More from news
Approximately 6 fully matching, plus 40 partially matching documents found.

Latest appointments

  • AZ names Brilique lead in Spain AZ names Brilique lead in Spain

    In this role Gribble will be responsible for the company's marketing of Brilique (ticagrelor) for acute coronary syndrome, including management, development and market access activities, and he will also be

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re an independent brand and marketing agency that believes our DNA is a little different from others. * A respectful,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics